[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623400":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":10,"responsibleParty":33,"collaborators":10,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":10,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":10,"enrollmentInfo":46,"targetDuration":49,"studyType":50,"phases":10,"briefSummary":51,"conditions":52,"keywords":57,"overallStatus":65,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":10},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Total Study Population",null,"This is an observational study with no predefined study groups",[13],"Other: No Intervention: Observational Cohort",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"No Intervention: Observational Cohort","This is an observational study. No experimental intervention (including drugs, devices, etc.) will be administered to the participants. The investigators will only collect clinical data and follow-up outcomes of the participants according to the study protocol.",[9],[20],{"name":21,"affiliation":5,"role":22},"Shuhang Wang","STUDY_DIRECTOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Dandan Cui, MD","CONTACT","+86 0316-5916013","cuidan@cicams.ac.cn",{"name":30,"role":26,"phone":31,"phoneExt":10,"email":32},"Shuhang Wang, PhD","13581809307","wangshuhang@cicams.ac.cn",{"type":34,"investigatorFullName":35,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","NING_LI","Chief, Office of Clinical Trial Center, CancerIHCAMS","100623400","baixiaoai-ai-companion-for-cancer-patient-follow-up-100623400",false,"NCT07396142","BaiXiaoAi AI Companion for Cancer Patient Follow-up","Application of BaiXiaoAi Companion AI in the Diagnosis, Treatment, and Follow-up Management of Oncology Patients: A Single-Center, Prospective, Exploratory Study","Inclusion Criteria:\n\n* Adults aged 18 years or older;\n* Patients with a confirmed diagnosis of malignant neoplasms who are currently undergoing treatment or in follow-up, or their primary caregivers;\n* Able to read and communicate in Chinese and independently use WeChat;\n* Willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Presence of severe psychiatric disorders (e.g., schizophrenia, bipolar disorder) or cognitive impairment (MMSE score \\\u003C 24);\n* Inability to use WeChat or communicate in Chinese;\n* Considered by the investigators to be unsuitable for participation due to psychological or physical conditions.","ALL","18 Years",{"count":47,"type":48},300,"ESTIMATED","6 Months","OBSERVATIONAL","This is a prospective, single-center, exploratory study designed to evaluate the accuracy, user engagement, and user experience of the BaiXiaoAi Companion AI. Upon signing the informed consent form and enrollment, a dedicated \"Doctor-Nurse-Patient-AI\" WeChat group will be established for each participant. Within the group, the BaiXiaoAi AI will provide timely responses based on patient communications and proactively push information regarding disease management and patient education.",[53,54,55,56],"Symptoms and Signs","Artificial Intelligence","Artificial Intelligence Mobile Application","Needs Assessment",[58,59,60,61,62,63,64],"WeChat-based AI companion","Tumor patients,","Cancer patients","Patient satisfaction","Symptom management","Emotional support","Clinical needs assessment","NOT_YET_RECRUITING","2026-02-01",{"date":68,"type":69},"2026-02-09","ACTUAL",{"date":71,"type":48},"2026-01-14",{"date":73,"type":48},"2027-11-30",{"name":5,"class":6}]